BOSTON, March 28, 2019 /PRNewswire/ -- IFM Therapeutics (IFM), a privately held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results